Company news
Monopar Therapeutics Inc. news in 2025
Monopar Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
November 12, 2025
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
November 8, 2025
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
October 14, 2025
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
September 22, 2025
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
September 22, 2025
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
September 14, 2025
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
September 2, 2025
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
August 11, 2025
Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers
June 10, 2025
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
June 2, 2025
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments
May 12, 2025
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
May 7, 2025
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
April 28, 2025
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
March 30, 2025
Decks in 2025
- AASLD 2025
Conference · 26 slides · November 2025
- ANA 2025
Conference · 14 slides · September 2025